21 research outputs found
Borrowing from '5-6' Lenders: Examining the Link Between Street Vendors' Profiles and Informal Borrowing Practices
No full textThis study examined the borrowing practices of street vendors in the Cogon public market, Cagayan de Oro, Philippines, with a specific focus on their reliance on the informal "5-6" lending system. The research assesses the relationship between street vendors' profiles (such as age, sex, type of products sold, and estimated daily sales) and their borrowing practices, including loan amount, interest rates, payment schemes, and the frequency of reborrowing. Utilizing a cross-sectional quantitative design, data were collected from 251 street vendors engaged in "5-6" lending. Chi-square tests were used to analyze the associations between vendor profiles and borrowing practices. Results revealed that most street vendors borrowed small-scale loans of P5,001-P10,000 (174.45), often with high interest rates of 20% over a two-month period, paying daily, which created a continuous debt and reborrowing cycle. Significant associations were found between age, daily sales, and credit value, as well as between product type, sex, and the frequency of reborrowing. The study concludes that the informal lending system imposes substantial financial burdens on street vendors, particularly women and those selling fast-moving goods, contributing to a cycle of debt dependency
The European Association of Preventive Cardiology
No full textDendale, P (corresponding author), Hasselt Univ, Heartctr Hasselt, Jessa Hosp, Stadsomvaart 11, B-3500 Hasselt, Belgium.
[email protected]; [email protected]
Non-alcoholic fatty liver disease, a new and growing risk indicator for cardiovascular disease
No full textJanssen, A (reprint author), Jessa Hosp, Clin Res Dept Cardiol, Heartctr Hasselt, Stadsomvaart 11, B-3500 Hasselt, Belgium.
[email protected]
Antithrombotic treatment strategies after PCI – Authors' reply
No full textVranckx, P (reprint author), Hasselt Univ, Jessa Ziekenhuis, Fac Med & Life Sci, Dept Cardiol & Intens Care, B-3500 Hasselt, Belgium.
[email protected]
Motivation of overweight patients with atrial fibrillation to lose weight or to follow a weight loss management program: a cross-sectional study
No full textAims Overweight increases the risk of recurrence and progression of atrial fibrillation (AF). This study assesses the knowledge of overweight AF patients about the relation between their weight and AF, to gauge their motivation losing weight and/or following weight reduction programs. Methods A multicenter cross-sectional descriptive study was performed at three Belgian hospitals. A validated self-developed questionnaire was presented to AF patients with a body mass index (BMI) >27 kg/m(2) and it addressed: motivation to reduce weight and its related factors; knowledge about the relation between weight and AF; and interest in weight reduction programs. Results One hundred and forty-three patients completed the questionnaire. 75.5% was currently motivated to reduce weight. Multivariate regression analysis showed that a higher BMI, a college/university degree, male gender, without hypertension, previous weight loss attempt(s) and living with a partner, were significantly associated with greater motivation for weight reduction. Only 69.9% of the patients was aware of the positive effect of weight reduction on the progression of AF. A completely home-based/telerehabilitation program was the preferred approach for 57.9% of the patients. ConclusionsFoundation Limburg Sterk Merk, Province of Limburg, Flemish Government, Hasselt University, Jessa Hospital and Ziekenhuis Oost-LimburgThis research is part of the Limburg Clinical Research Center (LCRC) UHasselt-ZOL-Jessa, supported by the Foundation Limburg Sterk Merk, Province of Limburg, Flemish Government, Hasselt University, Jessa Hospital and Ziekenhuis Oost-Limburg.Delesie, M (corresponding author), Antwerp Univ Hosp, Dept Cardiol, Wilrijkstr 10, B-2650 Edegem, Belgium.
[email protected]
Cardiovascular Volume Reserve in Patients with Heart Failure and Reduced Ejection Fraction
No full textThis study aimed to investigate the relationship between intravascular volume and intracardiac filling pressures in stable HF patients with reduced ejection fraction (HFrEF). A total of 40 HFrEF patients (LVEF 36 +/- 10%) (10 subjects with a pulmonary artery catheter) underwent intravascular volume expansion with 1 L hydroxyl-ethyl-starch over 3 h with coinciding intravascular volume measurements (technetium (99 tc)-labeled red blood cell technique). Intravascular blood volume increased from 5.0 +/- 1.0 L to 5.7 +/- 1.0 L (p < 0.0001). No change in clinical status, echocardiographic indices, or cardiac filling pressures was noticed. Invasively measured right atrial pressure and pulmonary arterial wedge pressure increased significantly immediately after start of infusion (4 +/- 2 mmHg to 8 +/- 4 mmHg; p = 0.01 and 10 +/- 3 mmHg to 15 +/- 6 mmHg; p = 0.01, respectively), decreased afterwards, and remained stable for 3 h (6 +/- 2 mmHg and 14 +/- 4 mmHg, respectively). The accuracy of cardiac filling pressure estimates to predict intravascular volume expansion was low (all AUC < 0.65).P.N is supported by The Frans Van de Werf Fund for Clinical Cardiovascular Research. P.N., P.M., and W.M. are researchers for the Limburg Clinical Research Program (LCRP) UHasselt-ZOL-Jessa, supported by the foundation Limburg Sterk Merk (LSM), Hasselt University, Ziekenhuis Oost-Limburg, and Jessa Hospital. P.N. and M.D. are supported by a research grant provided by Vision4Life-Sciences.Nijst, P (reprint author), Ziekenhuis Oost Limburg, Dept Cardiol, Schiepse Bos 6, B-3600 Genk, Belgium, Hasselt Univ, Doctoral Sch Med & Life Sci, Diepenbeek, Belgium.
[email protected]
The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature
No full textFamilial Mediterranean Fever (FMF) is the most prevalent genetic autoinflammatory disorder. In most patients, treatment with colchicine can prevent attacks of fever and inflammation. However, 5%-10% of patients are resistant to colchicine treatment, while a similar percentage cannot tolerate colchicine in doses needed to prevent attacks. For these patients, Canakinumab, a full human antibody against IL-1 beta, has been approved recently by the FDA and EMA. In this article, we present a systematic review of the long-term efficacy, safety, and tolerability of Canakinumab in FMF patients who cannot tolerate colchicine or who are resistant to colchicine treatment.van der Hilst, JCH (reprint author), Jessa Hosp, Dept Infect Dis & Immun, Stadsomvaart 11, B-3500 Hasselt, Belgium.
[email protected]
Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes
No full textBackground: The choice of glucose lowering agent in heart failure (HF)-patients can have a strong effect on HF-related adverse events, with some classes increasing and other classes reducing the risk. Little data is available about the choice of glucose lowering agents in HF-patients with type-2-diabetes. Methods: We performed a cross-sectional single centre point analysis of all patients with both a diagnoses of HF and type-2-diabetes followed in a tertiary HF-clinic. Medical records were used to determine the choice of current glucose lowering agent. Data at the time of cross-sectional analysis was used to determine potential eligibility to a sodium-glucose-linked-transporter-2-inhibitor (SGLT2-inhibitor) based on the enrolment criteria of the EMPAREG-OUTCOME-trial. Results: A total of 571 HF-patients with diabetes were assessed on June the first 2017. The majority of patients were either managed with one or two glucose lowering agents (43% respectively 34%), with metformin (N = 391;61%), Insulin (N = 278;49%) and sulfonylurea (N = 259;45%) being the most frequently employed treatments. SGLT2-inhibitor use was low (N = 7;1%). According to trial criteria 184 patients (32%) qualified for an SGLT2-inhibitor. With main reasons for ineligibility being a HbA1C = 2 glucose lowering agents from a class other than SGLT-2-inhibiton. Conclusion: Despite potential eligibility, SGLT2-inhibition remains an underused glucose lowering agent in this contemporary HF-population. Additional research is necessary on optimising its implementation in clinical practice, which might include switching glucose lowering therapies in patients at HbA1C-target.Pieter Martens is supported by a doctoral fellowship by the Research Foundation – Flanders (FWO, grant-number: 1127917N). Pieter Martens, and Wilfried Mullens are researchers for the Limburg Clinical Research Program (LCRP) UHasselt-ZOL-Jessa, supported by the foundation Limburg Sterk Merk (LSM), Hasselt University, Ziekenhuis Oost-Limburg and Jessa Hospital.Martens, P (corresponding author), Ziekenhuis Oost Limburg, Dept Cardiol, Schiepse Bos 6, B-3600 Genk, Belgium.
[email protected]
Diuretic response and effects of diuretic omission in ambulatory heart failure patients on chronic low‐dose loop diuretic therapy
No full textAims To study loop diuretic response and effect of loop diuretic omission in ambulatory heart failure (HF) patients on chronic low-dose loop diuretics. Methods and results Urine collections were performed on two consecutive days in 40 ambulatory HF patients with 40-80 mg furosemide (day 1 with loop diuretic; day 2 without loop diuretic). Three phases were collected each day: (i) first 6 h; (ii) rest of the day; and (iii) night. On the day of loop diuretic intake, the total natriuresis was 125.9 (86.9-155.0) mmol/24 h and urine output was 1650 (1380-2025) mL/24 h. There was a clear loop diuretic response with a natriuresis of 9.4 (6.7-15.9) mmol/h and a urine output of 117 (83-167) mL/h during the first 6 h, followed by a significant drop in natriuresis and urine output during the rest of the day [2.6 (1.8-4.8) mmol/h and 55 (33-71) mL/h] and night [2.2 (1.6-3.5) mmol/h and 44 (34-73) mL/h]. On day 2, after loop diuretic omission, the natriuresis and urine output remained similarly low the entire day, resulting in a 50% reduction in natriuresis [55.1 (33.5-77.7) mmol/24 h; P < 0.001] and a 31% reduction in urine output [1035 (875-1425) mL/24 h; P < 0.001] compared with the day of loop diuretic intake. Conclusion Patients with HF on chronic loop diuretic treatment still have a clear diuretic response phase, while loop diuretic omission leads to a significant drop in natriuresis and urine output, arguing against routine cessation of low-dose loop diuretics.Jeroen Dauw, Sebastien Deferm, Henri Gruwez and Wilfried Mullens are researchers for the Limburg Clinical Research Center (LCRC) UHasselt-ZOL-Jessa, supported by the foundation Limburg Sterk Merk (LSM), province of Limburg, Flemish government, Hasselt University, Ziekenhuis Oost-Limburg and Jessa Hospital.Mullens, W (corresponding author), Ziekenhuis Oost Limburg, Dept Cardiol, Schiepse Bos 6, B-3600 Genk, Belgium.
[email protected]
An observational study of innate immune responses in patients with acute appendicitis
No full textContains fulltext :
226185.pdf (Publisher’s version ) (Open Access
